Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 20/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18429046 | 0.98 | SLC6A2 (0.45) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL4610590 | 0.93 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL18469985 | 0.82 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL18429000 | 0.81 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 | |
| SCHEMBL6967580 | 0.80 | SLC6A4 (0.52) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL18469930 | 0.78 | OPRM1 (0.40) | — | |
| Hydrochloric Acid SCHEMBL9347602 | 0.77 | USP30 (0.44) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL9144078 | 0.77 | SLC6A4 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL18474883 | 0.77 | OPRM1 (0.41) | — | |
| SCHEMBL23487077 | 0.76 | SLC6A4 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331869-B1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| US-20180155315-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-07 | — | — | US | disclosed |
| US-20180022726-A1 | MUSCARINIC AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-01-25 | — | — | US | disclosed |
| US-9758506-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9758506-B2 | Muscarinic agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-09-12 | — | — | US | disclosed |
| US-20170037025-A1 | Muscarinic Agonists | NXERA PHARMA UK LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| WO-2017021730-A1 | MUSCARINIC AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022726-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | SLC6A2 591/4885SLC6A4 789/4885SLC6A3 636/4885 |
| US-20170037025-A1 | Muscarinic Agonists | CHRM1, CHRM2, CHRM3 | SLC6A2 591/4885SLC6A4 789/4885SLC6A3 636/4885 |
| US-20180155315-A1 | MUSCARINIC AGONISTS | CHRM1, CHRM2, CHRM3 | SLC6A2 591/4885SLC6A4 789/4885SLC6A3 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.